To include your compound in the COVID-19 Resource Center, submit it here.

Lilly reports additional Phase III breast cancer data for abemaciclib

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III MONARCH 3 trial in 493 postmenopausal women with hormone receptor-positive, HER2-negative, locoregionally recurrent or metastatic breast cancer showing

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE